Smith & Nephew stock (GB0009223206): sets sterling final dividend ahead of May payout

Smith & Nephew plc has confirmed the sterling equivalent of its 24.1 US cents final dividend for 2025, payable on May 27, 2026 to shareholders of record by March 27. The announcement came via SEC filing on May 12.

Smith & Nephew plc, a global medical technology company, has set the sterling amount for its final dividend of 24.1 US cents per ordinary share relating to the year ended December 31, 2025. The payment is scheduled for May 27, 2026, to shareholders on the register at the close of business on March 27, 2026. Eligible UK shareholders or those electing sterling will receive 17.78 pence per share, according to the SEC Form 6-K as of May 2026 and London Stock Exchange notice as of May 12, 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Smith & Nephew plc
• Sector/industry: Medical technology
• Headquarters/country: United Kingdom
• Core markets: Orthopaedics, sports medicine, ENT, advanced wound management
• Key revenue drivers: Knee implants, hip systems, endoscopy products
• Home exchange/listing venue: NYSE (SNN), London Stock Exchange (SN.)
• Trading currency: USD on NYSE, GBP on LSE

Smith & Nephew plc: core business model

Smith & Nephew plc develops, manufactures and markets medical devices worldwide, focusing on orthopaedics, sports medicine, ENT and advanced wound management. The company serves healthcare professionals and patients through innovative products that improve clinical outcomes and reduce costs. Its business model emphasizes research-driven innovation, global distribution and strategic acquisitions to expand its portfolio.

Headquartered in London, UK, Smith & Nephew generates significant revenue from the US market, making it relevant for American investors tracking medtech exposure. The firm reported underlying revenue growth in recent periods, driven by high-acuity procedures in orthopaedics and sports medicine, per its investor communications.

Main revenue and product drivers for Smith & Nephew plc

Orthopaedics accounts for the largest revenue share, with key products like the OXINIUM oxidized zirconium knee and hip implants, which offer durability advantages. Sports medicine contributes through endoscopy systems such as the REGENETEN bioinductive implant for rotator cuff repairs. Advanced wound management features products like PICO negative pressure therapy, widely used in the US for surgical and chronic wounds.

ENT products, including the TRUMPET stent for airway management, support diversified growth. The company's US listing on NYSE under ticker SNN provides direct access for US retail investors, with trading in USD.

Industry trends and competitive position

The global medtech sector faces trends like rising demand for minimally invasive procedures, aging populations and value-based care shifts. Smith & Nephew competes with Stryker, Zimmer Biomet and Medtronic, holding strong positions in knee reconstruction and arthroscopy. Its focus on robotics and digital surgery positions it for US market growth, where orthopaedics procedures exceed millions annually.

Why Smith & Nephew plc matters for US investors

With substantial US revenue exposure from hospitals and ambulatory centers, Smith & Nephew benefits from American healthcare spending trends. Its NYSE listing facilitates easy trading for US retail investors, alongside ADR structure for currency hedging. The company's innovation pipeline addresses key US challenges like joint replacement volumes amid obesity and active lifestyles.

Conclusion

Smith & Nephew plc's confirmation of its 2025 final dividend underscores ongoing shareholder returns amid steady medtech operations. The 24.1 US cents payout, with sterling details finalized, reflects financial stability for the year ended December 31, 2025. US investors can monitor upcoming results and product launches for further insights into its NYSE-traded shares.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.